| Display title | Chemistry:IONIS-GCCRRx |
| Default sort key | IONIS-GCCRRx |
| Page length (in bytes) | 2,750 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 247371 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>WikiEditor |
| Date of page creation | 03:15, 10 March 2023 |
| Latest editor | imported>WikiEditor |
| Date of latest edit | 03:15, 10 March 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | IONIS-GCCRRx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2. It has also been under investigation for the treatment of Cushing's syndrome, but no development has been... |
